Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 66c, Sales Miss
March 1, 2017 6:52 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $3.52, $0.66 better than the analyst estimate of $2.86. Revenue for the quarter came in at $81.1 million versus the consensus estimate of $86.13 million.
Total revenue for the fourth quarter of 2016 grew 346% to $81.1 million;Product sales increased to $9.1 million compared to $2.9 million in Q4... More